Evidence map›Paper›PMID 34461898›Full record

ArticleMalaria journal2021

Variable residual activity of K-Othrine® PolyZone and Actellic® 300 CS in semi-field and natural conditions in the Democratic Republic of the Congo.

Leonard M Ngwej, Emmanuel M Mashat, Clarence K Mukeng, Henri T Mundongo, Françoise K Malonga, Jean-Christophe K Kashala, Michael J Bangs

Abstract read
In one paragraph

Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Safety and Efficacy of Incorporating ActellicTropical medicine and infectious disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Leonard M NgwejChina Molybdenum/International SOS Malaria Control Programme, Tenke Fungurume Mining, Fungurume, Lualaba Province, Democratic Republic of Congo. dvmngwej@gmail.com.ORCID http://orcid.org/0000-0003-0167-1853
Emmanuel M MashatChina Molybdenum/International SOS Malaria Control Programme, Tenke Fungurume Mining, Fungurume, Lualaba Province, Democratic Republic of Congo.
Clarence K MukengSchool of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Henri T MundongoSchool of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Françoise K MalongaSchool of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Jean-Christophe K KashalaFaculty of Veterinary Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Michael J BangsChina Molybdenum/International SOS Malaria Control Programme, Tenke Fungurume Mining, Fungurume, Lualaba Province, Democratic Republic of Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndoor Residual Spray (IRS) against vector mosquitoes is a primary means for combating malaria transmission. To combat increased patterns of resistance to chemicals against mosquito vectors, alternative candidate insecticide formulations should be screened. With mortality as the primary endpoint, the persistence of residual efficacy of a polymer-enhanced pyrethroid suspension concentrate containing deltamethrin (K-Othrine® PolyZone-KOPZ) applied at 25 mg active ingredient (ai)/m

methodsFollowing standard spray application, periodic contact bioassays were conducted for at least 38 weeks on four types of wall surfaces (unbaked clay, baked clay, cement, and painted cement) sprayed with either KOPZ or ACS in simulated semi-field conditions. Similarly, two types of existing walls in occupied houses (painted cement and baked clay) were sprayed and examined. A colonized strain of female Anopheles arabiensis mosquitoes were exposed to treated or untreated surfaces (controls) for 30 min. For each wall surface test period, 40 treatment mosquitoes (4 cones × 10) in semi-field and 90 (9 cones × 10) in 'natural' house conditions were used per wall. 30 mosquitoes (3 cones × 10) on a matching unsprayed surface served as the control. Insecticide, wall material, and sprayed location on wall (in houses) were compared by final mortality at 24 h.

resultsInsecticide, wall material, and sprayed location on wall surface produced significant difference for mean final mortality over time. In semi-field conditions, KOPZ produced a 72% mean mortality over a 38-week period, while ACS gave 65% (p < 0.001). Painted cement wall performed better than other wall surfaces throughout the study period (73% mean mortality). In the two occupied houses, KOPZ provided a mean mortality of 88%, significantly higher than ACS (p < 0.001). KOPZ provided an effective residual life (≥ 80% mortality) between 7.3 and 14 weeks on experimental walls and between 18.3 and 47.2 weeks in houses, while ACS persisted between 3 and 7.6 weeks under semi-field conditions and between 7.1 and 17.3 weeks in houses. Household painted cement walls provided a longer effective residual activity compared to baked clay for both formulations. Greater mortality was recorded at the top and middle sections of sprayed wall compared to the bottom portion near the floor.

conclusionKOPZ provided longer residual activity on all surfaces compared to ACS. Painted cement walls provided better residual longevity for both insecticides compared to other surfaces. Insecticides also performed better in an occupied house environment compared to semi-field constructed walls. This study illustrates the importance of collecting field-based observations to determine appropriate product active ingredient formulations and timing for recurring IRS cycles.

Indexed as

AnophelesInsecticidesMosquito ControlMosquito VectorsNitrilesOrganothiophosphorus CompoundsPyrethrinsAnimalsDemocratic Republic of the CongoFemaleHousingMalariadecamethrinInsecticidesNitrilesOrganothiophosphorus Compoundspirimiphos methylPyrethrinsDeltamethrinDemocratic Republic of the CongoPirimiphos-methylResidual efficacy

Identifiers

PMID34461898
PMCPMC8406736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.